Affinia Therapeutics secured FDA acceptance of its AFTX-201 IND, enabling initiation of the Phase 1/2 UPBEAT study in BAG3-associated dilated cardiomyopathy with safety and tolerability as key endpoints.
ImmunityBio has launched a Phase 2 outpatient trial evaluating a chemotherapy-free combination of off-the-shelf CD19-targeted NK cells, ANKTIVA, and rituximab in relapsed or refractory indolent B-cell lymphomas.
February 12, 2026 is the expected record date for the spin-off of Atrium Therapeutics, which will hold Avidity's early-stage precision cardiology programs.
Piramal Pharma Solutions has commercialized a tablet-in-capsule drug delivery capability following a five-month technology transfer between its Ahmedabad development facility and its commercial manufacturing site in Pithampur, India.
AstraZeneca has shifted its U.S. listing to ordinary shares on the New York Stock Exchange as it targets $80 billion in annual revenue by 2030, alongside announcing major investment and licensing commitments in China.
